Differential ferrioxamine test in haemochromatosis and liver diseases

Gut
|September 1, 1969
PubMed

The effect of desferrioxamine is examined in more than 100 patients with liver disease, including haemochromatosis, using the differential ferrioxamine test. The procedure gives a reasonably accurate estimate of the size of the iron stores, as determined by multiple venesection, in patients with idiopathic haemochromatosis. Since desferrioxamine is not specific for storage iron, unequivocally abnormal results are not obtained unless the iron load exceeds about 2.3 g. In other forms of liver disease the effect of desferrioxamine is generally increased compared with that in controls. The results show no correlation with the serum iron level or the degree of hepatic siderosis. High values are usual in the presence of jaundice and overlap the range found in untreated haemochromatosis, adding to other evidence that desferrioxamine can derive iron from a hyperchelatable source unrelated to the stores. It is concluded that in liver diseases other than haemochromatosis the results of the test do not reliably reflect body storage iron content.

Related Concept Videos

Serum Laboratory Studies, Stool Test, Breath Test01:30

Serum Laboratory Studies, Stool Test, Breath Test

Gastrointestinal (GI) diagnostic studies are pivotal in confirming, ruling out, diagnosing, or staging various diseases, including cancers. Following diagnosis, allocating time for discussions with the patient and providing informational resources is crucial. Diagnostic assessments of the GI tract often occur in outpatient settings like endoscopy suites or GI labs. Preparation for these tests may include dietary restrictions, fasting, liquid bowel preparations, laxatives, enemas, and the...
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...